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Virtual screening (VS) is a discovery technique to identify novel compounds with therapeutic and preventive eﬃcacy against
disease. Our current focus is on the in silico screening and discovery of novel peroxisome proliferator-activated receptor-
gamma (PPARγ) agonists. It is well recognized that PPARγ agonists have therapeutic applications as insulin sensitizers in type
2 diabetes or as anti-inﬂammatories. VS is a cost- and time-eﬀective means for identifying small molecules that have therapeutic
potential. Our long-term goal is to devise computational approaches for testing the PPARγ-binding activity of extensive naturally
occurring compound libraries prior to testing agonist activity using ligand-binding and reporter assays. This review summarizes
the high potential for obtaining further fundamental understanding of PPARγ biology and development of novel therapies
for treating chronic inﬂammatory diseases through evolution and implementation of computational screening processes for
immunotherapeutics in conjunction with experimental methods for calibration and validation of results.
1.Introduction
Transdisciplinary research has become a common means
of addressing the most pressing societal problems. Past
discoveries of scientiﬁc hallmarks have favored exploring
the depths of established ideas across scientiﬁc disciplines
to better understand biological systems and processes. This
is possible because the wealth of scientiﬁc knowledge has
only scratched the surface of how biological systems work,
and often exploring the unknown intricacies of biological
networks requires knowledge of more than one scientiﬁc
realm.
The extreme amounts of information readily available to
the scientiﬁc community present a valuable and perpetually
renewing resource. However, this overabundance also poses
a problem. There is simply too much information within
too many areas of science for one person with expertise
in a single ﬁeld to rapidly make novel advances. Take, for
example, the question of what factors determine whether an
individual suﬀers from a particular disease. When designing
a treatment, one can look at the symptoms, the cause of the
symptoms, genetic diﬀerences between healthy and aﬄicted
individuals, genetic diﬀerences between individuals with the
same disease but slightly diﬀerent symptoms, methods for
treatingthesymptoms,methodsforcontrollingorcorrecting
the disease, and methods for screening for the disease.
This list includes, but is not limited to, disciplines such as
genetics, bioinformatics, biochemistry, pharmacology, and
medicine, and it is the combination of all these disciplines
that facilitates the development of eﬀective preventive and
therapeutic approaches.
In a more general sense, there is also an increasing need
for integrating computational and experimental approaches.
C o m p u t e r sh a v eb e c o m eal a r g ea n dv i t a lp a r to fs c i e n t i ﬁ c
exploration and serve to simplify and expedite processes
that could take months to years for an individual to
complete. First, computers allow for organization of sci-
entiﬁc knowledge. Second, they allow for sharing of ideas2 PPAR Research
and discoveries in an eﬀective and timely fashion. Third,
computers allow individuals to better analyze experimental
results and develop more eﬃcacious test methods. The
fourth and ultimate beneﬁt of computer technology to
science is improved eﬃciency due to a reduced necessity for
t i m e ,m o n e y ,a n dr e s o u r c e s .
Peroxisome proliferator-activated receptor (PPAR)
research is one of many areas that may beneﬁt from advances
in computational biology and other transdisciplinary
approaches. Mixtures of computational and experimental
studies have given insight into characteristics of PPARs,
particularly PPAR-gamma (PPARγ) and its modulators, as
well as the role of these proteins in treating type 2 diabetes
(T2D), gastrointestinal diseases, and genetic disorders
associated with glucose homeostasis and lipid uptake.
2.Characteristicsof PPARγ and
the ActivationProcess
PPARγ is one of three known PPAR isoforms (α, δ,a n dγ).
PPARs belong to the nuclear hormone receptor superfamily
and have been found to regulate inﬂammation, immunity,
and metabolism [1, 2]. Members of this superfamily are
structurally and functionally conserved transcription factors
that regulate both target gene expression and repression
after ligand binding occurs [3]. A diverse set of natural
and synthetic molecules is classiﬁed as ligands that can
induce activation and expression of PPARs. These ligands
include nutrients, nonnutrient endogenous ligands, and
drugs such as thiazolidinediones (TZDs) and ﬁbrates [1, 2,
4]. Known endogenous and dietary agonists include conju-
gated linoleic acid (CLA), 9-(S)-hydroxyoctadecadienoic (9-
HODE), 13-(S)-hydroxyoctadecadienoic (13-HODE) acid,
and 15-deoxy-Δ12,14-prostaglandin J2 (15d-PGJ2) [1, 5].
A great deal of literature focuses on increasing insulin
sensitivity by controlling PPARγ interactions and altering
gene expression of various transcription factors. PPARγ is a
component of an extensive group of controls for adipoge-
nesis and glucose homeostasis, and both of these processes
directly aﬀect obesity and T2D [6]. PPARγ is located in high
concentrations in adipocytes, and has also been found in
signiﬁcantamountsintheretina,cellsoftheimmunesystem,
and colonic epithelial cells [1, 7]. Functionally, PPARγ
downregulates the expression of proinﬂammatory cytokines
by antagonizing the activities of transcription factors such
as AP-1 and NF-κB, and favoring the nucleocytoplasmic
shuttling of the activated p65 subunit of NF-κB[ 2]. As a
consequenceoftheimportantrolesPPARsplayincontrolling
metabolic homeostasis and inﬂammatory processes, they are
all well recognized as molecular targets for drugs against
metabolic diseases, such as T2D [8–10], and treatment of
immunoinﬂammatory disorders.
Structurally, PPARγ is composed of a DNA-binding
domain(DBD),ahingeregion,andaligand-bindingdomain
(LBD). The ﬁrst step in PPARγ activation is disassociation
of corepressors after binding of retinoic acid (RA) to a
single retinoid X receptor (RXR) subunit. This step is
an essential part of numerous endocrine system pathways
[6]. The ligand-bound RXR then associates with ligand-
bound PPARγ. To become fully active, the PPARγ-RXRα
heterodimer requires association of coactivator molecules
[6]. Agonist binding to PPARγ regulates activity by causing
conformational changes to the LBD, which is composed of
approximately 250 amino acids near the C-terminal end of
the protein [11]. Mediation of activity is a direct result of
changes to the transcription activation function-2 (AF-2)
domain [6, 12]. These changes vary depending on the type
of ligand that binds to the LBD. Changes to AF-2 allow
for coactivator recruitment, followed by transcriptional
activation.
Co-activator recruitment is based on a LXXLL bind-
ing motif (nuclear receptor box) found on both PPARγ
and coactivators like steroid receptor coactivating factor-
1 (SRC-1) that associate for transcription induction after
the conformational change of the AF-2 region [3, 13, 14].
The DNA binding domains of PPARγ-RXRα interact with
PPAR response elements (PPREs) found within the genome
[15]. Such elements include 5  regions for aP2 and PEPCK
genes as part of adipogenesis, which suggests PPARγ plays
a major role in fat cell-speciﬁc gene function [15]. Though
PPARγ is typically known to interact with DNA, it can
also interact directly with other proteins to induce activity.
For example, as preadipocytes diﬀerentiate, expression of
C/EBPβ and C/EBPδ directly activate PPARγ and C/EBPα,
which promote further diﬀerentiation and full insulin sen-
sitivity [15]. Alternatively, binding by speciﬁc ligands can
induce activity as well. The use of TZDs in the treatment of
T2D improves insulin resistance by increasing GLUT-4 levels
and decreasing the levels of cytokines that induce insulin
resistance, such as TNF-α and IL-6 [15] by antagonizing
the activity of proinﬂammatory transcription factors [2].
Therefore, it is important to note that understanding the
interactions involved in coactivator recruitment is crucial
for predicting activity after ligand binding, and ultimately
treatment of insulin insensitivity and inﬂammation.
3. Agonists andthe Ligand-Binding
DomainofPPARγ
Fatty acids and lipid metabolites have been found to be
endogenous ligands for PPARγ.Ar e c e n ts t u d yb yW a k ue t
al. [16] gives insight into how these ligands bind covalently
to Cys285, thereby modifying PPARγ conformations. In par-
ticular, these covalent modiﬁcations induce rearrangement
of the side-chain network around the created covalent bond
i no r d e rt og e n e r a t ed i ﬀerent transcriptional strengths. This
attenuation of strength is speciﬁc to the ligand type and
conformation. Waku et al. also mention that Ile267 and
Phe287aretwokeyresiduesrepositionedbycovalentbinding
of fatty acids [16]. It is also important to note for some fatty
acids, formation of a complex containing two fatty acid units
is necessary for binding within the LBD of PPARγ [5].
Synthetic ligands that can interact with PPARγ can
be divided into at least three classes: full agonists, partial
agonists, and antagonists. Full agonists bind and alter the
conformation of the AF-2 domain allowing for coactivatorsPPAR Research 3
to bind for activation of genes for both adipogenic and
insulin sensitivity processes. Partial agonist binding leads to
a change that allows for recruitment of coactivators respon-
sible for insulin sensitivity without aﬀecting adipogenesis.
Antagonists show high aﬃnity, but do not activate PPARγ,
suggesting the conformational change to AF-2 is either not
enough to allow coactivator association or is similar to
that of the inactive conformation. A study conducted by
Kallenberger et al. showed that the dynamics of the AF-2
regionplaysamajorroleinthegeneticregulationcapabilities
of PPARγ. Binding of a ligand reduces AF-2 mobility and
allows for regulation of gene expression. Furthermore, the
AF-2regionofPPARγ canundergonaturalmutations,which
result in severe insulin insensitivity and cause noticeable
changes in dynamics of that AF-2 region [12].
PPARγ agonists typically possess a small polar region
and a hydrophobic region that form hydrogen bonds and
hydrophobic interactions, respectively, within the LBD.
Hydrogen bonding typically occurs between His323, Tyr473,
and His449 of the PPARγ LBD and carbonyl oxygens of
the ligand (Figure 1)[ 6, 13, 17]. Hydrogen bonding of the
ligand to Tyr473 is key to the stabilization of the AF-2
region [13,18].Thehydrophobicmoietyinteractswithother
residues in the cavity, such as Leu465, Leu469, and Ile472,
establishinghydrophobicinteractionstostabilizethedomain
(Figure 2)[ 6, 13, 17].
In the case of partial agonists, key interactions are
diﬀerent, which result in lesser degrees of AF-2 stabilization
and diﬀerential stabilization of distinct regions of the LBD
[5]. Either of these events leads to activation as a result of
a shift of the ligand polar group away from the hydrogen-
bonding residues. This shift can prevent hydrogen bonding
or lead to a diﬀerent hydrogen-bonding network. Changes
in the hydrophobic interactions between the ligand and
residues within the LBD also exist. The combination of these
events results in conformational changes diﬀerent enough
fromthosecausedbyfullagonistbindingtoelicitonlypartial
activation and recruitment of diﬀerent coactivators [5, 17].
Antagonists for PPARγ have not received the same
amount of research interest as the full and partial agonists.
Therefore, little information is available on the binding of
this type of ligand to the γ isoform. Antagonists for PPARα,
however, have provided insight into how ligands of this
class might interact with PPARγ due to the conservation
of the mode of corepressor binding. Typically, corepressors
bind to PPARα in the absence of ligand. The complex is
then stabilized by antagonists, which disrupt any potential
interactions with coactivators, and thereby prevent the
initiation of transcription [19].
The LBD of PPARγ is a large, T-shaped cavity [17]w i t h
a volume of approximately 1440 ˚ A3 [6, 17], which can easily
accommodate many diﬀerent ligands due to the dynamics of
the ligand-binding pocket [20]. It is important to note that
the type of ligand determines which coactivator associates
with the PPARγ-RXRα heterodimer. The coactivator then
determines the target gene for regulation and the direction
of regulation (up or down). Thus, knowing the ﬁnal
conformation of the LBD that is necessary to elicit a speciﬁc
activity is crucial for therapeutic development [3].
His449
Tyr473 His323
AF-2
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Figure 1: Rosiglitazone bound to LBD of PPARγ. Helices are
labeled with H, followed by a number. Key residues involved in
hydrogen bonding are labeled. Blue dashed lines represent bonding
interactions between the hydrogens of the residue and the oxygens
of the ligand. (PDB ID 3DZY).
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Figure 2: Rosiglitazone bound to LBD of PPARγ. Helices are
labeled with H, followed by a number. Some of the key residues
involved in hydrophobic interactions are labeled. (PDB ID 3DZY).
Until recently, available crystal structures for PPARγ
generally were composed solely of the PPARγ LBD with
a ligandbound,aRXRαLBDheterodimerizedtoPPARγ,and
a short segment of a coactivator protein. Chandra et al. have
published three new crystal structures (3DZU, 3DZY, and
3E00) for PPARγ composed of the DBD, the hinge region,
and the LBD with ligand bound [21]. These structures
are in complex with RXRα, polypeptides that mimic the
LXXLL motif for coactivator binding, and a short DNA
segment representative of a PPRE. Observations related to
heterodimerizationofPPARγ andRXRα,aswellasactivation
of response elements are reported in this study. The LBD
and DBD of PPARγ are positioned closely together, which
aids in coupling of the PPARγ LBD to the relatively wide
space between the LBD and DBD of RXRα [21]. The study
also discusses the polarity of the PPARγ-RXRα heterodimer,
which is determined by the (C)-terminal extension of PPARγ
and the DBD interactions of the two subunits. Table 1
contains a list of all currently available structures for PPARγ,4 PPAR Research
which can be found in RCSB’s PDB online database [22]
http://www.pdb.org/.
4.Docking
Docking can be deﬁned as predicting both ligand confor-
mation and orientation within a targeted binding site [52].
Experimentally derived crystal and NMR protein structures
are used as the basis for docking, and the physics involved
is based on what is known about atomic and molecular
interactions, as well as laws of thermodynamics. All docking
methods must include sampling ligand conformations, gen-
erating poses of the ligand within the receptor binding site,
and scoring the poses.
Before beginning a docking study, one must select
from three conformational searching methods: systematic,
random, and simulation. The systematic method explores
the degrees of freedom possessed by the torsional bonds
of a molecule. To achieve this goal, the ligand parts are
introduced incrementally in order to obtain an energetically
favorable conformation. Random searching, as the name
implies, is based on generating random torsional varia-
tions of an initial conformation to test against the target.
Simulation methods utilize molecular dynamics and energy
minimization, and serve best when coupled with one or both
of the above searching methods [52].
A large number of docking and dynamics software
packages and online servers exist (Table 2), many of which
are freely available for academic research. The variations in
calculation methods and results make each program slightly
diﬀerent. Therefore, the researcher must pick which docking
programs are ideal for his or her study. Studies have been
performed to assess which programs are ideal for speciﬁc
screening approaches or particular protein families. For
instance, Kellenberger et al. published a comparative evalu-
ation of eight widely used docking programs for screening
accuracy in 2004 [53]. Of the eight docking programs tested,
GLIDE, GOLD, and SURFLEX provided the best docking
and ranking accuracy within a 2.0 ˚ Ac u t o ﬀ for root-mean
squared deviation (RMSD), whereas QXP showed promising
docking accuracy but reduced ranking performance. For
ranking, FlexX outperformed QXP with percent scoring
errors of 15% and 55%, respectively. Eﬃcacy in screening
of a compound database was found with SURFLEX, with 8
hits for ligands that bind to a diﬃcult target out of 50 total
compounds. GLIDE, GOLD, and FlexX were deemed good
programs for virtual screening with hit values of 5, 4, and
4, respectively. Regarding docking times, FRED, which did
not perform as well with scoring and docking accuracy, took
the least amount of time to perform docking calculations of
the eight programs tested, followed by DOCK and FlexX. No
single program was deemed the best docking software, but
the study demonstrated that the characteristics of the ligand
and the target have a signiﬁcant eﬀect on the eﬃciency of the
docking program used [53].
5.VirtualScreening
Because the process of ﬁnding a novel compound showing
bioactivity can be time-consuming and expensive, structure-
based drug design has been established as a vital ﬁrst
step to therapeutic development [54]. Screening for ligand
conformations can be performed using a ligand-based or a
structure-based approach [55, 56]. Ligand-based design uses
known active and inactive compounds to generate a phar-
macophore [55], which is often used in conjunction with
quantitative structure-activity relationship (QSAR) analysis
to determine ligand-protein interactions. Receptor-based
design requires the availability of the receptor structure,
whichisusedtoexaminetheinteractionsthatoccurwithany
members of a large database of ligands [56]. Computational
screening of large databases of molecules against the three-
dimensional structure of a protein has the potential to
provide rapid and accurate prediction of the binding modes
and aﬃnities of possible hits for lead optimization. One
can prescreen a database of thousands of compounds and
narrow the ﬁeld of ligands to two or three potential hits
in a signiﬁcantly reduced amount of time compared to
laboratory experimental methods. This smaller group would
increase the eﬃciency of experimental assays and new
agonist discovery. Virtual Screening, which incorporates
high-throughput docking techniques, is a means to explore
the LBD of a protein and make predictions about ligand
binding. This technique categorizes ligands that bind to the
protein of interest and allows predictions to be made about
activation or inhibition of the protein.
Development begins with creating an algorithm that
can be followed to set up the testing, run the testing, and
ﬁnally analyze the results. Schneider and B¨ ohm deﬁne these
three issues that must be addressed when performing iter-
ative structure generation respectively as, the construction
problem, the docking problem, and the scoring problem
[57]. Deciding which protein crystal structure to use for all
ligands, establishing a set of test parameters, and deciding
which ligands to include in the test library make up the ﬁrst
part of the process. Typically, a crystal structure with the
highest resolution and fewest missing atoms and residues
will be selected. Setting parameters involves re-docking of
published structures to reproduce experimentally observed
docking conformations [52]. The compound database,
which can contain numbers of compounds in the thousands
[58], should contain small molecules that, based on known
chemical interactions between residues of the binding site
and known ligands, will bind in varying degrees to the
protein of interest and potentially yield the desired eﬀect
(e.g., conformational change and activation or inhibition
of protein). Protein ﬂexibility is also an important and
necessary part of predicting orientations and interactions for
many protein families [54], and therefore time should be
taken to consider how to incorporate receptor ﬂexibility as
well as the binding site microenvironment (i.e., water and/or
ions in the binding site). Once the conditions for docking
have been established, docking, which is the second step, is
relatively straightforward.
The ﬁnal step, analysis, can often be the most daunting
due to the variety of ways output can be interpreted and
analyzed. The type of program used to perform simulations
has a signiﬁcant eﬀect on analysis methods because of
the information returned. Some programs may be betterPPAR Research 5
Table 1: PDB IDs of published crystal and NMR structures for PPARγ with various ligands bound. Resolution values are in Angstroms (˚ A).
The “Reference number” columns list references for each PDB ID. The citations for these are present in the reference section. All PDB IDs
list Homo sapiens as the protein source except 1ZGY (Rattus norvegicus). Access date: 23 March 2009.
Structure ID Resolution (˚ A) Release date Reference number Structure ID Resolution (˚ A) Release date Reference number
1FM6 2.1 02/16/01 [6] 2Q6S 2.4 10/23/07 [23]
1FM9 2.1 02/16/01 [6] 2Q8S 2.3 10/14/08 [24]
1I7I 2.3 03/09/02 [25] 2QMV n/a (NMR) 09/02/08 [26]
1K74 2.3 12/05/01 [27] 2VSR 2.0 08/19/08 [5]
1KNU 2.5 12/19/02 [28] 2VST 2.3 08/19/08 [5]
1NYX 2.7 07/15/03 [29] 2VV0 2.5 08/19/08 [5]
1PRG 2.2 01/13/01 [13] 2VV1 2.2 08/19/08 [5]
1RDT 2.4 11/09/04 [30] 2VV2 2.8 08/19/08 [5]
1WM0 2.9 09/07/04 [31] 2VV3 2.8 08/19/08 [5]
1ZEO 2.5 04/25/06 [32] 2VV4 2.3 08/19/08 [5]
1ZGY 1.8 07/26/05 [33] 2ZK0 2.4 2/24/09 [16]
2ATH 2.3 08/25/06 [34] 2ZK1 2.6 2/24/09 [16]
2F4B 2.1 02/14/06 [35] 2ZK2 2.3 2/24/09 [16]
2FVJ 2.0 05/16/06 [36] 2ZK3 2.6 2/24/09 [16]
2G0G 2.5 05/16/06 [37] 2ZK4 2.6 2/24/09 [16]
2G0H 2.3 05/16/06 [37] 2ZK5 2.5 2/24/09 [16]
2GTK 2.1 09/26/06 [38] 2ZK6 2.4 2/24/09 [16]
2HFP 2.0 09/19/06 [39] 3B3K 2.6 10/28/08 [40]
2HWQ 2.0 08/07/07 [41] 3BC5 2.3 11/18/08 [42]
2HWR 2.3 08/07/07 [41] 3CDP 2.8 1/13/09 [43]
2I4J 2.1 04/17/07 [17] 3CDS 2.7 12/30/08 [40]
2I4P 2.1 04/17/07 [17] 3CS8 2.3 06/03/08 [44]
2I4Z 2.3 04/17/07 [17] 3CWD 2.4 07/08/08 [45]
2OM9 2.8 04/24/07 [46] 3D24 2.1 06/10/08 [47]
2P4Y 2.3 01/08/08 [48] 3D6D 2.4 12/30/08 [40]
2POB 2.3 03/18/08 [49] 3DZU 3.2 10/28/08 [21]
2PRG 2.3 07/19/99 [13] 3DZY 3.1 10/28/08 [21]
2Q59 2.2 10/23/07 [23] 3E00 3.1 10/28/08 [21]
2Q5P 2.3 10/23/07 [23] 3ET0 2.4 2/17/09 [50]
2Q5S 2.0 10/23/07 [23] 3ET3 2.0 2/17/09 [50]
2Q61 2.2 10/23/07 [23] 3PRG 2.9 08/30/99 [3]
2Q6R 2.4 10/23/07 [23] 4PRG 2.9 05/27/99 [51]
Table 2: List of some commonly used molecular dynamics and docking software packages with developer URL. This is not intended to be a
comprehensive list of all available dynamics and docking programs available. Available programs are typically free to download for academic
use, but some require the purchase of a license for use.
Dynamics Docking
Program Developer Site Program Developer site
Amber http://ambermd.org/ AutoDock http://autodock.scripps.edu/
AMMP http://www.cs.gsu.edu/∼cscrwh/progs/progs.html FlexX http://www.biosolveit.de/FlexX/
BALLview http://www.ballview.org/ FRED http://www.eyesopen.com/
CHARMM http://www.charmm.org/ GLIDE http://www.schrodinger.com/
GROMACS http://www.gromacs.org/ GOLD http://www.ccdc.cam.ac.uk/
LOOS Library http://membrane.urmc.rochester.edu/Software Sculptor http://sculptor.biomachina.org/
YASARA http://www.yasara.org/ SLIDE http://www.bch.msu.edu/
YUP http://rumour.biology.gatech.edu/YammpWeb/ SURFLEX http://www.tripos.com/
ZMM http://www.zmmsoft.com/ UCSF DOCK http://dock.compbio.ucsf.edu/6 PPAR Research
suited for calculating inhibition constants and free energy
of binding estimations than others, whereas still other
programs may provide more variables for consideration.
There are many diﬀerent approaches to analyzing results
that one can take for scoring the results of a docking study,
and these approaches involve examination of interactions on
either a fragment or atomic level [57].
6. Limitationsof VirtualScreening
Because VS is not, as of yet, a stand-alone process, ligand-
binding and reporter assays are essential processes for
validating in silico results. Docking predicts ligands that may
elicit the desired activity, and assays further reﬁne the group
of viable candidates to a select group of hits, which, at a
speciﬁc concentration, will activate the protein of interest.
Furtherresearchintolesser-understoodbiochemicalpro-
cesses is necessary to improve upon the reliability of VS as a
stand-alone process. These processes include protein ﬂexibil-
ityandinduced-ﬁtadaptations,theroleofwaterinsolvation,
desolvation and ligand binding, and the involvement of
electrostatics [52, 59]. Though these unknowns can prove
to be problematic when looking at a single computational
method, combining strategies is a way to improve upon
successful hit rates. Overall, VS saves time and resources
whensearchinglibrariesofcompoundstonarrowcandidates
down to a handful of potential hits that can then be tested
experimentally. There is also potential to ﬁnd hits that may
nothavebeendiscoveredusingexperimentalprocessesalone.
Another factor that can limit VS productivity is the
amount of information available whenbuilding a compound
library. An information-rich environment is available when
considering natural compounds for the treatment and pre-
vention of diseases. Natural plant extracts typically contain
a vast number of components that one would need to sift
through in order to ﬁnd the one compound or multiple
synergisticcompoundsthatelicitadesiredmechanisticaﬀect
(i.e., activation of PPARs). VS would prove useful after
fractionation of natural extracts and chemical elucidation of
key peaks to aid in identifying which compounds within a
library are the bioactive compounds. This has the potential
to minimize the need for serial HTS when testing for a lead
candidate. It is important to note that fractionation is not a
necessary step for VS, but can be useful for guiding database
building when examining natural extracts for bioactivity.
7.DockingandVirtualScreeningSuccesses
Despite the present inability of VS to replace HTS, the two
can be complementary approaches to candidate pharma-
ceutical and nutraceutical searching because of the poten-
tial for one method to ﬁnd activators or inhibitors for
which the other method does not show results [59]. Klebe
[59] mentions in a review of VS strategies a comparison
study performed by two groups searching for Escherichia
coli dihydrofolate reductase inhibitors from a database of
approximately 50,000 compounds. The VS portion of the
study revealed a number of compounds previously unknown
as inhibitors due to insuﬃcient concentrations of the
compounds being used during experimental testing [59–62].
Klebe also provides a list of targets that have previously been
addressed by virtual screening. These targets include nuclear
receptorssuchasretinoic acidreceptorandthyroidhormone
receptor [59].
8.Relevance toPPARγ Agonist Discovery
Docking techniques would prove useful in the development
of new PPAR-based therapeutics, including in silico screen-
ing of synthetic agonists and natural compounds from plant
extracts (i.e., botanicals), all of which have shown promise
in the treatment and prevention of immunoinﬂammatory
diseases through PPARγ agonism. Docking and simulation
techniques provide a means to prescreen for and enrich
compounds with PPARγ agonism and thereby increase the
eﬃciency of HTS. Docking also allows for structure-based
searches for analogues and derivatives of known agonists.
To date, there have been several studies utilizing standard
docking methods [63–66] and VS methods [60, 63, 67–70].
Most of these studies focus on derivatives or analogues of
a particular compound showing high aﬃnity for PPARγ.
Studies of this nature can serve two purposes: identify hits
fortherapeuticdevelopmentandprovideinsightintoligand-
protein interactions and ligand selectivity.
Xu et al. [64] published a study in 2003 in which docking
methods were used to look at interactions between PPARγ
and eighteen known synthetic and natural agonists in order
to determine the pharmacophore of PPARγ agonists. The
group determined that PPARγ agonists must have a polar
head group and hydrophobic tail in order to form necessary
hydrogen bonding and hydrophobic contacts with the LBD,
respectively [64].
In another study, Lu et al. [63]c o n d u c t e das t r u c t u r e -
based VS search for PPARγ partial agonists as candidates for
treatment of T2D with fewer side eﬀects than full agonists.
The search revealed a class of ligands that could then be
used to test against PPARγ. Two compounds of the class were
identiﬁed as partial agonists with selectivity among the three
PPAR subtypes, and would serve as candidates for further
testing. Using VS, they were able to suggest determinants in
ligand speciﬁcity. The computational results were coupled
with X-ray crystallography and assessment of in vitro and in
vivo protein activity [63].
A study regarding natural products identiﬁed as PPARγ
agonists conducted by Salam et al. [68] also utilized
structure-based VS to identify 29 potential agonists for
experimental testing. Of those compounds, 6 were found
to induce PPARγ transcriptional activity in vitro. The study
also provided insight into the mechanism underlying the
ﬂavonoid-induced conformational change and activation of
PPARγ [68].
9. FutureDirections
Naturally occurring compounds with preventive or ther-
apeutic activity (nutraceuticals) represent a widely usedPPAR Research 7
Complementary and Alternative Medicine (CAM) modality
and are an alternative to pharmaceuticals (i.e., TZDs)
for treating various chronic diseases such as T2D. These
natural compounds can modulate gene expression [71]
and are typically safer than synthetic counterparts. In the
case of T2D, nutraceuticals have the potential to decrease
the risk of myocardial infarction, weight gain, and edema
associated with current synthetic PPARγ agonist treatments
[10, 72]. Unfortunately, ﬁnding a compound that elicits a
desired activity is not always easy because isolating a single
compound from a bioactive extract is time consuming and
expensive [73] and the mechanism by which the compound
works is often unknown [74]. VS, in combination with
conventional experimental methods, has the potential to
put the discovery of bioactive botanical constituents in a
better competitive position with mainstream pharmaceu-
tical research by reducing time and costs. For instance,
in a study published by Rollinger et al. [75], a chemi-
cal feature-based pharmacophore modeling VS technique,
in combination with ethnopharmacology, was utilized to
identify inhibitors for cyclooxygenase (COX) I and II. Of
the thousands of compounds listed in the four databases
used (WDI, NCI, NPD, and DIOS), the success rate of
ﬁnding known inhibitors within these three-dimensional
databases was enhanced through the use of VS techniques
[75].
A preliminary comparison of a small group of PDB
PPARγ structures shows an overall conservation of backbone
conformation across the available structures. This is relevant
to the selection of a single macromolecule for large-scale
automated testing. These ﬁndings suggest it is possible
to select one macromolecule for all ligand types with a
limited degree of error. It is important to note that though
there is a relative consensus position for all key residues,
some variation in the positions of key residues due to
ligand interactions are present. Therefore, this issue must be
considered and several structures must be examined when
deciding on a single macromolecule crystal structure for VS.
Another computational method that may prove useful
is molecular dynamics (MD), which involves the use of
computational chemistry to predict the dynamics of com-
plex molecular systems and the macroscopic properties of
those systems based on detailed atomic knowledge [76].
Implementing MD would prove useful for examination of
conformational changes and molecular interactions, which
would allow for expansion upon what is known about how
PPARs interact with ligands and other macromolecules.
To discover potential nutraceutical/CAM hits, further
assessment of PPARγ and ligand characteristics is necessary
to determine the best screening approach and which scoring
functions compare for analysis. If the components of an
extract are known or if one can speculate as to which
compounds are present, a database of chemically related
compounds could be created to test against PPARγ,a n d
a smaller hit group can be identiﬁed for experimenta-
tion. Another necessary element is collecting experimen-
tally proven properties for comparison to computationally
derived data. Future work could also encompass ﬁnding
coagonists and pan-agonists for PPAR subtypes.
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